We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Atacand (Candesartan) Real Life Study (Real Life)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00620178
Recruitment Status : Completed
First Posted : February 21, 2008
Last Update Posted : December 2, 2010
Information provided by:

Brief Summary:
This study is a Swedish historical cohort study in patients prescribed Atacand or Cozaar for hypertension by selected primary care centres. Data will be extracted anonymously from electronic medical records. In addition, data regarding morbidity and mortality will be collected by merging the cohort with the following national registries: the Hospital Discharge Register (Slutenvårdsregistret), the Cause of Death Register and the Heart Intensive Care Admission (RIKS-HIA)

Condition or disease Intervention/treatment
Hypertension Drug: Candesartan Cilexetil Drug: Losartan

Layout table for study information
Study Type : Observational
Estimated Enrollment : 14000 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: A REtrospective Study on the Effects of cAndesartan vs. Losartan on Blood Pressure, Health Care Consumption and cardiovascuLar Events In a "Real-liFe" GP sEtting in Sweden
Study Start Date : March 2008
Actual Primary Completion Date : February 2009
Actual Study Completion Date : February 2009

Resource links provided by the National Library of Medicine

Group/Cohort Intervention/treatment
Drug: Candesartan Cilexetil
oral once daily dose
Other Name: ATACAND

Drug: Losartan
once daily oral dose
Other Name: COZAAR

Primary Outcome Measures :
  1. The primary efficacy objective is to investigate, on basis of 'first to event', the development of new cardiovascular diseases (CVD). [ Time Frame: 1999 - 2007 ]

Secondary Outcome Measures :
  1. Cardiovascular disease states and procedures in the background and over the entire observation period will be identified by use of ICD-9 and ICD-10 coding for diseases of the cardiovascular system. Specifically are death, acute cardiovascular events, new [ Time Frame: 1999 - 2007 ]
  2. Health care consumption will be assessed as contacts with health care providers, in-hospital time periods for cardiovascular disease states with associated therapeutic procedures, and times spent within various levels of care (e.g. ICU and general ward). [ Time Frame: 1999 - 2007 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   17 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Eligible subjects are all patients found in EPS systems at the participating centres, who were prescribed candesartan (ATC-C09CA06) or losartan (C09CA01) for hypertension from 1 January 1999 - 31 December 2004 inclusive. The first found prescription is designated as index.

Inclusion Criteria:

  • Recorded blood pressure prior to therapy of > 140 and/or 90 mmHg
  • Diagnosed as hypertensive within 15 months
  • First prescription of Cozaar or Atacand between 1 January 1999 and 31 December 2007, inclusive

Exclusion Criteria:

  • Previous prescription within 15 months any drug from the ATC groups C02, C03, C07 - C09 inclusive

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00620178

Layout table for location information
Research Site
Uppsala, Sweden
Sponsors and Collaborators
Layout table for investigator information
Principal Investigator: Jan Stålhammar, MD Eriksbergs vårdcentral
Layout table for additonal information
Responsible Party: Anders Ljunggren, MD, AstraZeneca
ClinicalTrials.gov Identifier: NCT00620178    
Other Study ID Numbers: NIS-CSE-ATA-2008/1
First Posted: February 21, 2008    Key Record Dates
Last Update Posted: December 2, 2010
Last Verified: December 2010
Keywords provided by AstraZeneca:
blood pressure
cardiovascular disease
health care consumption
Additional relevant MeSH terms:
Layout table for MeSH terms
Vascular Diseases
Cardiovascular Diseases
Candesartan cilexetil
Anti-Arrhythmia Agents
Antihypertensive Agents
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action